Buprenorphine prevents and reverses the expression of chronic etorphine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells.
Buprenorphine is an opiate drug with a mixed agonist-antagonist profile and has therapeutic efficacy in attenuating drug craving and addiction. Because the adenylyl cyclase system has been implicated in the biochemical basis of opiate withdrawal phenomena, we have compared the acute and chronic effects of buprenorphine with the full opiate agonist etorphine on cyclic AMP (cAMP) synthesis in the human neuroblastoma cell SK-N-SH. Both drugs acutely inhibited prostaglandin (PG)E1-stimulated cAMP accumulation; the inhibition caused by either drug was prevented by pretreatment with the opiate antagonist naltrexone or with pertussis toxin. Chronic treatment of the cells with etorphine induced an increase in PGE1-stimulated cAMP synthesis which was observed after withdrawal of the inhibitory drug. Chronic treatment with buprenorphine appeared to have the opposite effect, resulting in an attenuated PGE1 stimulation; additionally, buprenorphine prevented the etorphine-induced enhancement in cAMP synthesis, whether administered before or after prolonged incubation of the cells with etorphine. The attenuating effect of buprenorphine occurred within 5 min and was prevented by a prior application of naltrexone, but could not be reversed by a subsequent treatment with antagonist. These findings suggest that buprenorphine was binding (pseudo)irreversibly to the opiate receptor, resulting in a persistent inhibition of cAMP synthesis which masks the etorphine-induced enhancement of adenylyl cyclase activity. This hypothesis was confirmed by experiments demonstrating that treatment of the cells with buprenorphine significantly reduced available opiate receptor binding sites despite extensive washing of the cells to remove unbound buprenorphine. These pharmacodynamic actions of buprenorphine may be relevant to its therapeutic efficacy in treating drug abuse and addiction.
Thomas
J M
JM
Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Hoffman
B B
BB
D000262:Adenylyl Cyclases / Q000187:drug effects* / Q000378:metabolism; D000527:Alprostadil / Q000494:pharmacology; D002047:Buprenorphine / Q000378:metabolism / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D000242:Cyclic AMP / Q000096:biosynthesis / Q000378:metabolism; D004347:Drug Interactions; D005048:Etorphine / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D009447:Neuroblastoma / Q000201:enzymology*; D017450:Receptors, Opioid, mu / Q000378:metabolism / Q000502:physiology; D012680:Sensitivity and Specificity; D013268:Stimulation, Chemical; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D017450:Receptors, Opioid, mu; D002047:Buprenorphine; D005048:Etorphine; D014212:Tretinoin; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D000527:Alprostadil